BrightInsight, Inc. (San Jose, CA), provider of a regulated Internet of Things (IoT) platform for biopharma and medtech, has announced global digital health partnership with AstraZeneca. AZ will develop apps, algorithms, Software as a Medical Device and connected devices on top of the BrightInsight Platform “that enhance and personalize care while making overall healthcare delivery more efficient for patients and providers.” The first major program the companies are collaborating on is in the chronic disease management space. “We quickly dismissed the concept of building our own custom platform so we could focus instead on developing transformational digital health solutions...” commented Karan Arora, Chief Commercial Digital Officer and Global Vice President, AstraZeneca. “We selected BrightInsight because its pre-built, compliant platform accelerates our time to market while allowing us to focus on digital health innovation and leveraging our clinical know-how to improve patient outcomes instead of the underlying infrastructure.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.